Kornimate/medical-research-clean huggingface dataset:
spatial cognitive training

Conditions: Blind

Summary: this study is designed to see if doing regular training on a spatial imagery task leads to improvements in the ability to do the trained spatial imagery task and in the ability to get around in everyday activities.

the investigators will recruit 40 blind participants, randomized by the investigators' cvnr statistician into two groups. one group will undergo the experimental intervention (spatial cognitive training) and the other will undergo a control intervention involving letter-number matching. the participants will include women and minorities in proportion to the demographics of the veteran population attending the atlanta va.

Eligibility criteria:
inclusion criteria: * inability to perceive visual stimuli, i.e. no light perception, with stable visual loss over the past year * the investigators anticipate that causes of blindness will be ocular, including: * glaucoma * diabetic retinopathy and macular degeneration * the most common causes of blindness in veterans * as well as possibly late-onset leber's optic atrophy and ocular trauma (in the absence of tbi) * to minimize heterogeneity due to variations in age and the duration of visual loss, the investigators will restrict enrollment to veterans and non-veterans over the age of 50 who lost light perception within the last 5 years, and who have completed standard o\&m training. * from a practical standpoint, this also enables the investigators to focus on participants who can potentially benefit most from the proposed intervention. exclusion criteria: * participants will be excluded if they have any neurological condition, such as: * tbi * history of blast exposure * stroke * brain tumors * epilepsy, etc. * participants will also be excluded if mri scanning is contra-indicated, e.g.: * due to an implanted device such as a pacemaker * or foreign bodies of ferromagnetic nature * cognitive screening will be performed using the repeatable battery for assessment of neuropsychological status (rbans, randolph, 1998) and participants with cognitive impairment will be excluded based on a score of 1.5 sd below the mean for the verbal memory index. * the investigators will test participants' hearing using a validated screening questionnaire (screening version of the hearing handicap inventory for the elderly, hhie-s, wentry \& weinstein, 1983, lichtenstein et al., 1988) followed by assessment of audiometric pure tone (0.5, 1.0, 2.0, 4.0 khz) hearing thresholds in the cvnr sound booth. * participants with more than mild hearing loss (hhie score \>8 or audiometric thresholds \>40db) will be excluded (wentry \& weinstein, 1983; wilson, 2009), given that the investigators are relying on audio cues. * the investigators will also exclude visually impaired veterans who are dependent on a wheelchair or scooter for mobility, as they will not be able to take part in the real-world task.
clinical trial to investigate safety, tolerability, pharmacokinetics, pharmacodynamics, and efficacy of da-4505 as a single agent and in combination with pembrolizumab in adult patients with locally advanced or metastatic solid tumors

Conditions: Locally Advanced or Metastatic Solid Tumors

Summary: this study is an open-label, phase 1/2a, first-in-human, dose-escalation, dose-expansion, and proof-of-concept study to investigate safety, tolerability, pharmacokinetics, pharmacodynamics, and efficacy of da-4505 as a single agent and in combination with pembrolizumab in adult patients with locally advanced or metastatic solid tumors.


Eligibility criteria:
inclusion criteria: 1. aged 18 and older. 2. capable of giving signed informed consent. 3. diagnosed with particular disease characteristics. 4. expected survival ≥ 3 months. 5. eastern cooperative oncology group (ecog) performance status ≤ 1. 6. a female patient is eligible to participate if she is not pregnant or breastfeeding. 7. a male patient is eligible to participate if he agrees to remain abstinent or use a male condom when having sexual intercourse with a wocbp, or if he has had a bilateral vasectomy. 8. have measurable disease by revised recist v1.1 criteria. exclusion criteria: 1. inability to take oral medications or gastrointestinal abnormalities potentially impacting absorption. 2. current enrollment or past participation in another clinical trial. 3. unresolved adverse reactions (except alopecia) from previous cancer-directed therapy. 4. use of cancer-directed therapies, including chimeric antigen receptor t cell therapy. 5. autologous transplantation within 60 days. 6. prior allogeneic transplantation. 7. major surgery within 30 days, or unresolved complications after a major or minor surgery. 8. history of or currently active cardiovascular disease. 9. clinically significant respiratory, hepatic, renal, gastrointestinal, endocrinological, hematological, or neurological disorders. 10. history of other malignancy.
the effect of experimentally decreasing sedentary behaviour on subjective well-being

Conditions: Sedentary Lifestyle; Quality of Life

Summary: this study will explore the causality between outcomes of subjective well-being and sedentary behavior, through experimentally decreasing the sedentary behavior levels of university students. half of the eligible participants will receive a behavioral counseling intervention to increase non-sedentary behavior over one week, while the other half will receive no instructions. after one week, all participants will receive no instructions and continue to wear the inclinometer for another week.

the relationship between subjective well-being (swb) and sedentary behavior (sb) has been briefly explored. however, the causality of the relationship (i.e., do higher levels of sb cause changes in swb, or vice-versa) has not been fully examined. experimentally decreasing sb and observing the potential subsequent effect on swb may help to determine the causation between sb and swb. a sedentary sample of full-time university students attending western university will be recruited. upon obtaining consent, demographics will be taken. sedentary behavior will be confirmed objectively through inclinometer wear for 1-week. upon confirmation of sufficient sedentary time, participants will complete questionnaires assessing past-week: swb, sb, physical activity, depression, and anxiety questionnaires. participants will also be randomized to either a behavioral counseling intervention group, or a no-contact control group. participants will then continue wearing the inclinometer for 1 week. after the intervention week, participants will complete the questionnaires again, after which all participants will be told to continue daily behavior, and wear the inclinometer for another week. upon completion of this follow-up week, participants will complete questionnaires again.

Eligibility criteria:
inclusion criteria: * 18 years of age or older * full-time student attending western university * able to read and write in english * objectively report ≥7 hours of average daily sedentary time, via activpal4 inclinometer exclusion criteria: * self-reporting a mental illness * currently having a physical disability that would prevent walking

Keywords: sedentary behaviour subjective well-being university students
ak104 in neoadjuvant treatment of cervical cancer

Conditions: Cervical Cancer

Summary: phase ii open label study to evaluate the safety and efficacy of ak104 (anti-pd-1 and ctla-4 bispecific antibody) in neoadjuvant treatment of cervical cancer.


Eligibility criteria:
inclusion criteria: 1. age≥18 \& ≤75. 2. eastern cooperative oncology group (ecog) performance status of 0 or 1. 3. histologically or cytologically confirmed diagnosis of primary cervical squamous cell carcinoma. 4. according to the 2018 international federation of cervical cancer obstetrics and gynecology (figo) staging standard, the patient was diagnosed in stage ib2-iia2. 5. has not received any treatment before. 6. has at least one measurable lesion based on response evaluation criteria in solid tumors (recist) 1.1 assessed by investigator. 7. has adequate organ function. exclusion criteria: 1. has an active autoimmune disease that has required systemic treatment in the past 2 years (i.e. with use of disease modifying agents, corticosteroids or immunosuppressive drugs). replacement therapy (e.g., thyroxine, insulin or physiologic corticosteroid replacement therapy for adrenal or pituitary insufficiency, etc.) is not considered a form of systemic treatment. 2. active hepatitis b or hepatitis c. 3. history of severe bleeding tendency or coagulation disorder. 4. undergone major surgery within 30 days prior to the first dose of study treatment. 5. pregnant or lactating female patients. 6. drug or alcohol abuse. 7. has a history or current evidence of any condition, therapy, or laboratory abnormality that might confound the results of the study, interfere with the subject's participation for the full duration of the study, or is not in the best interest of this subject to participate, in the opinion of the treating investigator.
noninferiority trial of mitraclip implantation strategies: 1 clip vs. 2 clips in patients with functional mitral regurgitation

Conditions: Mitral Regurgitation Functional

Summary: implantation of the mitraclip has become the most frequently used percutaneous technique to treat significant (grade 3+ or 4+) mitral regurgitation (mr) in elderly patients deemed inoperable or at high surgical risk. in europe, about two-thirds of patients treated with the mitraclip suffer from mr of functional origin secondary to ischemic or dilated cardiomyopathy. at present, there is debate among operators on whether stabilizing/supporting a single adequately implanted clip with a second clip is beneficial for patients with functional mr.

implantation of the mitraclip has become the most frequently used percutaneous technique to treat significant (grade 3+ or 4+) mitral regurgitation (mr) in elderly patients deemed inoperable or at high surgical risk. in europe, about two-thirds of patients treated with the mitraclip suffer from mr of functional origin secondary to ischemic or dilated cardiomyopathy. at present, there is debate among operators on whether stabilizing/supporting a single adequately implanted clip with a second clip is beneficial for patients with functional mr. purpose to demonstrate the noninferiority of a 1-clip strategy vs. a 2-clip strategy of mitraclip implantation, when the second clip in the 2-clip study arm is implanted for stabilizing/supporting purposes.

Eligibility criteria:
inclusion criteria: * absence of a structural abnormality of the mitral valve giving rise to mr. * mr severity of us grade 3+ or 4+ of central or noncentral origin * patient must consent to randomization in the hybrid operating theater upon successful implantation of a single mitraclip. written informed consent must be provided prior to the mitraclip procedure. exclusion criteria: * patients with primary regurgitation

Keywords: mitral regurgitation transcatheter mitral valve repair mitraclip
vertebral osteosynthesis in degenerative lumbar stenosis with spondylolisthesis

Conditions: Spondylolisthesis

Summary: study to evaluate the superiority of the osteosynthesis associated with a decompressive surgery in comparison with a simple decompressive surgery in the treatment of lumbar degenerative stenosis with spondylolisthesis

randomized, comparative study on 152 patients with degenerative spondylolisthesis l4-l5 confirmed by radiography with radicular pain for whom the antalgic and anti-inflammatory treatment are not efficient for at least 3 months. patients randomized in 2 parallel groups (each group with 76 patients) * one group with decompressive surgery + osteosynthesis * one group with decompressive surgery study duration : 18 months, including a selection visit, an inclusion with the surgical intervention, 3, 12, 18 months' follow up visits and a follow up call at 6 months.

Eligibility criteria:
inclusion criteria: * patients with degenerative spondylolisthesis l4-l5 confirmed by radiography with radicular pain for whom the antalgic and anti-inflammatory treatment are not efficient for at least 3 months; * patients who agree to take part in the study and to sign an informed consent form exclusion criteria: * contre-indications to surgery or to vertebral isolated fixation l4-l5 * previous lumbar surgery * work accidents * psychiatric troubles that may interfere with the clinical evaluation * pregnant women or women who could be pregnant during the study * patient under special supervision or trusteeship * refusal to sign the informed consent form * no public health insurance cover

Keywords: spondylolisthesis, decompressive surgery, osteosynthesis
effect of fluid deresuscitation with central venous pressure target 0-4 mmhg in septic shock patients

Conditions: Septic Shock

Summary: a scientific research to prove the safety and effectiveness of tvs 0 - 4 mmhg as a target of resuscitation using furosemide, to improve perfused vessel density (pvd) \> 25 mm / mm2, aki stage (based on kdigo criteria), ci \> 2.5 cc / min / m2 , prevent the incidence of intubation, reduce the duration of ventilator use \<120 hours and reduce the length of icu stay in patients with septic shock after resuscitation

the study aims to evaluate the effectiveness of deresuscitation with target cvp 0 - 4 mmhg on septic shock patients in the icu on capillary perfusion density, aki stage (based on kdigo criteria), the incidence of intubation, duration of use of mechanical ventilation, and length of stay in the icu which can reduce the number of morbidity and mortality. the study evaluates the difference in capillary perfusion density, aki stage (based on kdigo criteria), and the cardiac index value between groups septic shock patients with cvp 0-4 mmhg on the 7th day after deresuscitation compared with the control group (cvp 8-10 mmhg on the first 7th day after being given deresuscitation). the study evaluates the difference in the number of intubation incidents, duration of use ventilators, and care in the icu between groups of patients with septic shock cvp 0 - 4 on day 28 after being given a degree of comparison with a control group (cvp 8-10 mmhg on day 28th after being deresuscitation).

Eligibility criteria:
inclusion criteria: * septic shock patients who meet the diagnosis criteria for quick sofa and kdigo 1 stage aki (creatinine value 1.5 times or creatinine value\> 0.3 initial or urine production \<0.5 ml/kg/hour for 6-12 hours * patients, both men and women, in the age range of 18 - 60 years * patients who experience post clean operative sepsis * patients who agree to attend the study by signing informed consent exclusion criteria: * patients with primary heart problems, right or heart failure suffer from congenital heart disease * have severe chronic obstructive pulmonary disease, patients with severe pleural effusion * patients who, based on ultrasound examination, found stones or tumors in the kidney during the study period * ckd patients are based on history taking and physical examination * dnr (do not resuscitate) patients

Keywords: deresuscitation central venous pressure septic shock furosemide
overview of telemedicine in children with type 1 diabetes

Conditions: Telemedicine; Diabetes Mellitus, Type 1; Children, Only

Summary: assessment of the proportion of pediatric patients with type 1 diabetes with access to remote monitoring

in the follow-up of type 1 diabetes in children, contact with families besides the appointements with medical et paramedic staff (paediatrician, diabetologist, nurses) is very common but not well coded, start from telehealth hubs (like mydiabby), to less unofficial contact by phone or email. this is even more so widespread since generalization of continuous glucometer (freestyle, dexcom,...), which allowed a quick data transfer to the medical staff. some studies had shown that telemedicine in diabetes allowed a better glycemic control and a higher implication in the desease. indeed, in 1999 already, hba1c significant improvement was shown when patients was regularly called by a nurse (thompson et al.). same finding was demonstrated in schiaffini and al. clinical trial in 2016. this trial also shown a better adhesion to the follow up into the telemedicine group. despite all of this studies, in france, remote monitoring isn't standardised and financed, except the national experimentation etapes which promotes and financially supports the deployment of remote monitoring projects around the territory.

Eligibility criteria:
inclusion criteria: * children with type 1 diabetes exclusion criteria: * no consent

Keywords: diabetes mellitus type 1 children telemedicine
a study of nivolumab + chemotherapy or nivolumab + ipilimumab versus chemotherapy in non-small cell lung cancer (nsclc) participants with epidermal growth factor receptor (egfr) mutation who failed 1l or 2l egfr tyrosine kinase inhibitor (tki) therapy

Conditions: Non-Small-Cell Lung Carcinoma

Summary: the main purpose of this study is to determine whether nivolumab + chemotherapy is effective as compared to chemotherapy in the treatment of patients with egfr mutation, nsclc who failed first line (1l) or second-line (2l) egfr tki therapy.


Eligibility criteria:
inclusion criteria: * confirmed stage iv or recurrent egfr mutated nsclc with disease progression on one or two prior lines of treatment with egfr tkis (allowed tkis must be approved by the local health authority, including but not limited to erlotinib, gefitinib, afatinib, dacomitinib and osimertinib). in osimertinib treated subjects, t790 testing is not required. * no evidence of exon 20 t790m mutation obtained at progression on prior first- or second-generation egfr tki therapy. for participants who were treated with osimertinib, t790m testing is not required. * measurable disease according to response evaluation criteria in solid tumors version 1.1 (recist 1.1) * available tumor sample for programmed death-ligand 1 (pd-l1) immunohistochemical (ihc). * participants are eligible if central nervous system (cns) metastases are considered to be adequately controlled/treated before or during the screening period and participants are neurologically returned to baseline (except for residual signs or symptoms related to the cns treatment) for at least 2 weeks prior to randomization. in addition, participants must be either off corticosteroids, or on a stable or decreasing dose of ≤10 mg daily prednisone (or equivalent) for at least 2 weeks prior to randomization). participants with asymptomatic cns metastasis are eligible. * eastern cooperative group (ecog) performance status 0-1 * life expectancy is at least 3 months exclusion criteria: * known egfr mutation, t790m positive who failed 1l first- or second-generation tki should receive osimertinib first as the standard of care (soc). these participants are only eligible if they fail osimertinib as 2l. * who have progressed within 3 months of the first dose of 1l or 2l egfr tki. * carcinomatous meningitis * active, known or suspected autoimmune disease are excluded * alk translocation * known sclc transformation * prior treatment with an anti-pd-1, anti-pd-l1, anti-pd-l2, anti-cd137, or anti-ctla-4 antibody, or any other antibody or drug specifically targeting t-cell co-stimulation or checkpoint pathways other protocol defined inclusion/exclusion criteria apply
a prospective, single center, observational study to assess the rapid recovery after cardiac surgery using sternalock xp

Conditions: Rigid Plate Fixation; Median Sternotomy

Summary: the primary objective of this study is to evaluate the post-operative rapid recovery in patients treated with sternalock xp for rigid sternal fixation with sternal precautions less restrictive than standard of care.

the primary efficacy endpoint of evaluation is defined by the post-operative time back to prior work or life through patient diary. the primary safety endpoint of evaluation is defined by the incidence rate of sternal complications (dswi \& sswi) at 30 days post-op. the secondary endpoints of evaluation up to 60-days post-operative are defined by: * quality of recovery after surgery (qor-15) * days alive out of the hospital and at home (dah) * disability-free survival (whodas 2.0.) * pain scores: likert scale 1-10 * opioid pain medication usage * spirometry: inspiratory vital capacity (ivc), as a measure of lung function recovery

Eligibility criteria:
inclusion criteria: * male and female * ≥ 18 years of age, no upper limit * undergoing a full standard midline sternotomy as part of an elective or urgent cardiac surgical procedure \[i.e., coronary artery bypass graft (cabg) and/ or valve replacement\] and closed with the sternalock xp rigid fixation system * willing to sign informed consent prior to the cardiac surgical procedure * willing and able to provide follow-up information up to 60-days post-operative exclusion criteria: inclusion criteria * male and female * ≥ 18 years of age, no upper limit * undergoing a full standard midline sternotomy as part of an elective or urgent cardiac surgical procedure \[i.e., coronary artery bypass graft (cabg) and/ or valve replacement\] and closed with the sternalock xp rigid fixation system * willing to sign informed consent prior to the cardiac surgical procedure * willing and able to provide follow-up information up to 60-days post-operative exclusion criteria pre-operative * emergent or salvage cardiac acuity, i.e., patients undergoing cardiopulmonary resuscitation en-route to the operating room or prior to induction of anesthesia * active or latent infection (with positive culture) * documented foreign body sensitivity, allergy, or intolerance to metals. * rapid bone absorption condition, metabolic bone disease, cancer, tumor, or tumor like condition of the bone, end-stage malignant disease, or other unexplained disease. * mental/ neurologic conditions rendering patients unwilling or incapable of following post-operative care instructions. * functional disability affecting gait, balance or mobility. operative * delayed sternal closure required for any reason (e.g., sent to icu with open chest wound) * intra-operative conditions that, in the opinion of the operating surgeon, would preclude the use of rigid plate fixation. * insufficient quantity of sternal bone or limited blood supply as assessed by the operating surgeon using his or her professional judgment at the time of closure. * intraoperative death prior to device placement
relationship between serum 1,25-dihydroxy vitamin d and markers of bone metabolism in renal dysfunction patients

Conditions: Chronic Kidney Disease-Mineral and Bone Disorder

Summary: this cross-sectional study was conducted, including those subjects tested for 1,25(oh)2d during jan 2015-dec 2021. estimated glomerular filtration rate (egfr) was calculated and subjects were classified into chronic kidney disease (ckd) stages. associations between biochemical marker, calcium, phosphorus, magnesium, alkaline phosphatase, 1,25(oh)2d and ckd stages was determined.


Eligibility criteria:
inclusion criteria: • data of serum 1,25(oh)2d available exclusion criteria: • serum1,25(oh)2d is not available

Keywords: renal dysfunction bone metabolism marker 1,25(oh)2 vitamin d